News

High Dose Stem Cell Transplant Performed

Stem Cells (STEM) has announced the first patient to receive a high dose of one million purified human neural stem cells (HuCNS-SC®) in their Phase 1/2 clinical trial. This followed an independent review by the Data Safety Monitoring Committee, which found no safety issues with proceeding to the high dose. The 16-patient trial is designed to evaluate the [Read More]

New Stem Cell Eye Treatment Study Beginning

(Updated March 12, 2017) MD Stem Cells has announced a new and extensive stem cell study  to determine effectiveness of stem cells in ophthalmic disease. The company has been named collaborator for the new Stem Cell Ophthalmology Treatment Study (SCOTS), being conducted in Florida. Conditions eligible for the new study include retinal diseases such as age-related [Read More]

Eylea Approved in Europe for CRVO

Regeneron Pharmaceuticals’ Eylea (aflibercept) treatment for central retinal vein occlusion (CRVO) has been approved by the European Commission. Eylea was approved in the United States for the treatment of neovascular (wet) age-related macular degeneration (AMD) in 2011, and for macular edema following CRVO in 2012. The drug has also been approved in Europe, Japan, Australia, [Read More]

What Is Low Vision Rehabilitation?

Low vision rehabilitation is like physical therapy for someone who has lost a limb. Its purpose is to develop strategies to maximize or substitute for diminished sight in order to maintain independence and a sense of self-worth. This rebuilding and reinforcement of the visual foundation is accomplished through identification of goals, introduction to assistive devices, [Read More]